Stock Analiz

JNJ vs PFE stock comparison

Johnson & Johnson vs. Pfizer · data as of November 13, 2026

Johnson & Johnson (JNJ) has a market value of about $687.9B, Pfizer (PFE) about $164.7B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Pfizer $63.6B.

On our five checks Johnson & Johnson scores higher: 2.6 out of 5 (average) against 2.2 (weak).

By area, the stronger company is Pfizer on value; Pfizer on future growth; Johnson & Johnson on track record; Johnson & Johnson on financial health; Johnson & Johnson on shareholder returns.

Pfizer is cheaper on earnings (P/E 41.3 vs. 43.4).

Johnson & Johnson leads on 12 of the compared lines and Pfizer on 12.

Side by side

JNJPFE
Size and price
Market cap$687.9B$164.7B
Share price$285.75$28.89
Score
Overall score (of 5)2.62.2
Value01
Future growth02
Track record42
Financial health42
Shareholder returns54
Valuation
P/E (TTM)43.441.3
Forward P/E25.110.1
Price / free cash flow33.414.0
Price / sales6.92.6
EV / EBITDA26.716.1
PEG2.91—
DCF value vs. price−39%−31%
Business
Revenue$99.3B$63.6B
Net income$16.1B$4.0B
Free cash flow$20.6B$11.8B
Net margin16.2%6.3%
Gross margin (5-yr avg.)69.1%66.5%
ROIC (5-yr avg.)16.6%11.4%
Growth
Revenue growth (1 yr)6.0%-1.7%
Revenue growth (5 yrs, per year)2.7%8.5%
EPS growth (5 yrs, per year)14.9%-3.6%
Balance sheet and payouts
Net cash (cash minus debt)-$27.4B-$51.7B
Dividend yield1.88%5.95%
Shareholder yield2.8%5.9%
Analysts
Upside to average target−2%+5%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, PFE TTM to September 27, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Johnson & Johnson or Pfizer?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Johnson & Johnson scores 2.6 out of 5 and Pfizer 2.2; the table shows where each one is stronger.

Is Johnson & Johnson cheaper than Pfizer?

On trailing earnings, Pfizer trades at a P/E of 41.3 and Johnson & Johnson at 43.4, so Pfizer is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Johnson & Johnson or Pfizer?

Over five years Pfizer grew revenue about 8.5% a year and Johnson & Johnson about 2.7% a year.

Which pays a higher dividend?

Johnson & Johnson yields 1.88% and Pfizer 5.95%.

Full Johnson & Johnson analysis → Full Pfizer analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.